Канада - английский - Health Canada

bayer inc - gadoxetate disodium - solution - 181.43mg - gadoxetate disodium 181.43mg - other diagnostic agents

Канада - английский - Health Canada

liebel-flarsheim canada inc - gadoversetamide - solution - 330.9mg - gadoversetamide 330.9mg - other diagnostic agents

Канада - английский - Health Canada

liebel-flarsheim canada inc - gadoversetamide - solution - 330.9mg - gadoversetamide 330.9mg - other diagnostic agents

Канада - английский - Health Canada

liebel-flarsheim canada inc - gadoversetamide - solution - 330.9mg - gadoversetamide 330.9mg - other diagnostic agents

Канада - английский - Health Canada

jubilant draximage inc. dba jubilant radiopharma - gadopentetate dimeglumine - solution - 469mg - gadopentetate dimeglumine 469mg - other diagnostic agents

Канада - английский - Health Canada

guerbet - gadoterate meglumine - solution - 376.9mg - gadoterate meglumine 376.9mg - other diagnostic agents

Соединенные Штаты - английский - NLM (National Library of Medicine)

bayer healthcare, inc. - gadofosveset trisodium (unii: xm33q67uvh) (gadofosveset - unii:e65rw73phs) - injection - 244 mg in 1 ml - vasovist is indicated for use as a contrast agent in magnetic resonance angiography (mra) to evaluate aortoiliac occlusive disease (aiod) in adults with known or suspected peripheral vascular disease [see clinical studies (14) ]. history of a prior allergic reaction to a gadolinium-based contrast agent. pregnancy category c there are no adequate and well-controlled studies of vasovist in pregnant women. in animal studies, pregnant rabbits treated with gadofosveset trisodium at doses 3 times the human dose (based on body surface area) experienced higher rates of fetal loss and resorptions. because animal reproduction studies are not always predictive of human response, only use vasovist during pregnancy if the diagnostic benefit justifies the potential risks to the fetus. in reproductive studies, pregnant rats and rabbits received gadofosveset trisodium at various doses up to approximately 11 (rats) and 21.5 (rabbits) times the human dose (based on body surface area). the highest dose resulted in maternal t

Канада - английский - Health Canada

liebel-flarsheim canada inc - gadoversetamide - solution - 330.9mg - gadoversetamide 330.9mg - other diagnostic agents

Австралия - английский - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadobenate dimeglumine, quantity: 529 mg/ml - injection, solution - excipient ingredients: water for injections - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) indicated for: for use in adults for the enhancement of magnetic resonance imaging (mri) of the liver and central nervous system (cns) for diagnostic use only. for use in adult patients with suspected or known vascular disease for contrast-enhanced magnetic resonance angiography of the abdominal or peripheral arteries where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadobenate dimeglumine, quantity: 529 mg/ml - injection, solution - excipient ingredients: water for injections - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) indicated for: for use in adults for the enhancement of magnetic resonance imaging (mri) of the liver and central nervous system (cns) for diagnostic use only. for use in adult patients with suspected or known vascular disease for contrast-enhanced magnetic resonance angiography of the abdominal or peripheral arteries where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease.